Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression.

Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol (2005) 3.69

Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J Virol (2001) 3.20

Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J Virol (2000) 2.37

Predictors of early mortality in a cohort of human immunodeficiency virus type 1-infected african children. Pediatr Infect Dis J (2004) 2.30

Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol (2005) 2.25

Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins. Microbiol Mol Biol Rev (2001) 2.06

Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J Virol (2003) 1.96

HIV and the chemokine system: 10 years later. EMBO J (2006) 1.88

Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. J Virol (2006) 1.87

Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS. J Virol (2001) 1.80

Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J Virol (2001) 1.79

A macaque model of HIV-1 infection. Proc Natl Acad Sci U S A (2009) 1.76

Viral persistence in vivo through selection of neutralizing antibody-escape variants. Proc Natl Acad Sci U S A (2000) 1.72

Animal models for HIV/AIDS research. Nat Rev Microbiol (2012) 1.71

Titration of an SIVmac251 stock by vaginal inoculation of Indian and Chinese origin rhesus macaques: transmission efficiency, viral loads, and antibody responses. AIDS Res Hum Retroviruses (2001) 1.69

Intrinsic susceptibility of rhesus macaque peripheral CD4(+) T cells to simian immunodeficiency virus in vitro is predictive of in vivo viral replication. J Virol (2000) 1.47

SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys. Retrovirology (2008) 1.45

In vivo attenuation of simian immunodeficiency virus by disruption of a tyrosine-dependent sorting signal in the envelope glycoprotein cytoplasmic tail. J Virol (2001) 1.45

Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques. J Virol (2006) 1.45

Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120. J Virol (2003) 1.42

HIV RNA level in early infection is predicted by viral load in the transmission source. AIDS (2010) 1.41

A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. J Virol (2009) 1.34

Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J Virol (2007) 1.30

Quintuple deglycosylation mutant of simian immunodeficiency virus SIVmac239 in rhesus macaques: robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain. J Virol (2001) 1.29

Human immunodeficiency virus type 1 derivative with 7% simian immunodeficiency virus genetic content is able to establish infections in pig-tailed macaques. J Virol (2007) 1.27

Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions. J Virol (2005) 1.26

Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course. J Virol (2001) 1.25

Unusual distribution of mutations associated with serial bottleneck passages of human immunodeficiency virus type 1. J Virol (2000) 1.25

Evolutionary history and attenuation of myxoma virus on two continents. PLoS Pathog (2012) 1.22

In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. J Virol (2004) 1.19

Consequences of cytotoxic T-lymphocyte escape: common escape mutations in simian immunodeficiency virus are poorly recognized in naive hosts. J Virol (2004) 1.17

Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection. J Virol (2009) 1.17

Evidence for persistent, occult infection in neonatal macaques following perinatal transmission of simian-human immunodeficiency virus SF162P3. J Virol (2006) 1.15

HIV-1 dynamics revisited: biphasic decay by cytotoxic T lymphocyte killing? Proc Biol Sci (2000) 1.15

Pediatric HIV-1 in Kenya: pattern and correlates of viral load and association with mortality. J Acquir Immune Defic Syndr (2009) 1.14

Pathogenesis of primary R5 human immunodeficiency virus type 1 clones in SCID-hu mice. J Virol (2000) 1.14

IFN-alpha-induced upregulation of CCR5 leads to expanded HIV tropism in vivo. PLoS Pathog (2010) 1.11

Clinical significance of HIV-1 coreceptor usage. J Transl Med (2011) 1.07

Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1. J Virol (2011) 1.05

Highly pathogenic simian immunodeficiency virus mne variants that emerge during the course of infection evolve enhanced infectivity and the ability to downregulate CD4 but not class I major histocompatibility complex antigens. J Virol (2002) 1.04

Unique pattern of convergent envelope evolution in simian immunodeficiency virus-infected rapid progressor macaques: association with CD4-independent usage of CCR5. J Virol (2003) 1.03

Feline leukemia virus envelope sequences that affect T-cell tropism and syncytium formation are not part of known receptor-binding domains. J Virol (2000) 1.03

Innate host barriers to viral trafficking and population diversity: lessons learned from poliovirus. Adv Virus Res (2010) 0.96

Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response. Virology (2010) 0.95

Human immunodeficiency virus evolution towards reduced replicative fitness in vivo and the development of AIDS. Proc Biol Sci (2007) 0.95

During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein. J Virol (2001) 0.93

Vpx is critical for SIVmne infection of pigtail macaques. Retrovirology (2012) 0.93

Generation of lineage-related, mucosally transmissible subtype C R5 simian-human immunodeficiency viruses capable of AIDS development, induction of neurological disease, and coreceptor switching in rhesus macaques. J Virol (2013) 0.91

Simian immunodeficiency virus variants that differ in pathogenicity differ in fitness under rapid cell turnover conditions. J Virol (2005) 0.89

Adaptive evolution of simian immunodeficiency viruses isolated from 2 conventional-progressor macaques with encephalitis. J Infect Dis (2008) 0.87

Affinofile profiling: how efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV. Virology (2013) 0.85

Conservation of Nef function across highly diverse lineages of SIVsmm. Retrovirology (2009) 0.85

Effect of synaptic transmission on viral fitness in HIV infection. PLoS One (2012) 0.84

Early- and intermediate-stage variants of simian immunodeficiency virus replicate efficiently in cells lacking CCR5. J Virol (2003) 0.83

Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol-anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16. J Virol (2011) 0.82

Trimeric glycosylphosphatidylinositol-anchored HCDR3 of broadly neutralizing antibody PG16 is a potent HIV-1 entry inhibitor. J Virol (2012) 0.81

Heavily glycosylated, highly fit SIVMne variants continue to diversify and undergo selection after transmission to a new host and they elicit early antibody dependent cellular responses but delayed neutralizing antibody responses. Virol J (2008) 0.81

Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees. J Virol (2000) 0.81

Changes in simian immunodeficiency virus reverse transcriptase alleles that appear during infection of macaques enhance infectivity and replication in CD4+ T cells. Virology (2007) 0.80

Breaking Barriers to an AIDS Model with Macaque-Tropic HIV-1 Derivatives. Biology (Basel) (2012) 0.80

Relative replication capacity of phenotypic SIV variants during primary infections differs with route of inoculation. Retrovirology (2010) 0.79

Evolution of the fittest ends in tragedy. Nat Med (1999) 0.79

Glycosyl Phosphatidylinositol-Anchored C34 Peptide Derived From Human Immunodeficiency Virus Type 1 Gp41 Is a Potent Entry Inhibitor. J Neuroimmune Pharmacol (2016) 0.79

HIV-1 Transmission, Replication Fitness and Disease Progression. Virology (Auckl) (2008) 0.78

A decrease in albumin in early SIV infection is related to viral pathogenicity. AIDS Res Hum Retroviruses (2009) 0.78

HIV transmission biology: translation for HIV prevention. AIDS (2015) 0.77

Dendritic cell-mediated HIV-1 infection of T cells demonstrates a direct relationship to plasma viral RNA levels. J Acquir Immune Defic Syndr (2010) 0.77

On the relative fitness of early and late stage Simian immunodeficiency virus isolates. Theor Popul Biol (2007) 0.77

Accessory genes confer a high replication rate to virulent feline immunodeficiency virus. J Virol (2013) 0.77

Characteristics of a pathogenic molecular clone of an end-stage serum-derived variant of simian immunodeficiency virus (SIV(F359)). J Virol (2001) 0.76

The Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1. J Virol (2016) 0.75

Stepping toward a macaque model of HIV-1 induced AIDS. Viruses (2014) 0.75

A phylogenomic analysis of Marek's disease virus reveals independent paths to virulence in Eurasia and North America. Evol Appl (2017) 0.75

Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA (2000) 10.40

The origin of mutants. Nature (1988) 8.92

Cancer linked to Alzheimer disease but not vascular dementia. Neurology (2009) 4.83

Gender differences in HIV-1 diversity at time of infection. Nat Med (2000) 4.69

Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J Virol (1997) 4.19

Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology (2003) 3.99

Epidemiological study of sudden and unexpected deaths due to arteriosclerotic heart disease. Circulation (1966) 3.90

Rapid method for screening dried blood samples on filter paper for human immunodeficiency virus type 1 DNA. J Clin Microbiol (1999) 3.88

Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol (2000) 3.83

The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81

Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med (1992) 3.42

Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis (2000) 3.02

Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1. J Virol (1995) 2.98

Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J Virol (1999) 2.90

Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J Virol (1997) 2.88

Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet (1997) 2.88

Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science (1992) 2.83

The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis (2001) 2.79

Strong sequence conservation among horizontally transmissible, minimally pathogenic feline leukemia viruses. J Virol (1988) 2.62

Silent MRI infarcts and the risk of future stroke: the cardiovascular health study. Neurology (2001) 2.55

The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA (1999) 2.42

Distribution of brain HIV load in AIDS. Brain Pathol (1998) 2.36

Evolution of envelope sequences from the genital tract and peripheral blood of women infected with clade A human immunodeficiency virus type 1. J Virol (1998) 2.21

Characterization of a CD4-expressing macaque cell line that can detect virus after a single replication cycle and can be infected by diverse simian immunodeficiency virus isolates. Virology (1995) 2.08

Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread. J Virol (1998) 2.07

Genital shedding of human immunodeficiency virus type 1 DNA during pregnancy: association with immunosuppression, abnormal cervical or vaginal discharge, and severe vitamin A deficiency. J Infect Dis (1997) 2.02

Sudden death in arteriosclerotic heart disease; the case for preventive medicine. Am J Cardiol (1969) 1.99

Changes in the extracellular envelope glycoprotein of variants that evolve during the course of simian immunodeficiency virus SIVMne infection affect neutralizing antibody recognition, syncytium formation, and macrophage tropism but not replication, cytopathicity, or CCR-5 coreceptor recognition. J Virol (1998) 1.98

Use of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 to assess the performance of viral RNA quantitation tests. J Clin Microbiol (2000) 1.95

Inoculation of baboons and macaques with simian immunodeficiency virus/Mne, a primate lentivirus closely related to human immunodeficiency virus type 2. J Virol (1988) 1.91

Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS (2001) 1.88

Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset. Neurology (2004) 1.87

Human immunodeficiency virus DNA in urethral secretions in men: association with gonococcal urethritis and CD4 cell depletion. J Infect Dis (1995) 1.86

The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis (1991) 1.84

Viral genetic determinants of T-cell killing and immunodeficiency disease induction by the feline leukemia virus FeLV-FAIDS. J Virol (1991) 1.83

Nationwide cerebrovascular disease morbidity study. Stroke (1972) 1.82

Cell-free human immunodeficiency virus type 1 in breast milk. J Infect Dis (1998) 1.74

Antibiotics as growth promotants: mode of action. Anim Biotechnol (2002) 1.71

Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge. J Virol (2003) 1.70

Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA (2000) 1.69

Vascular stiffness in women with systemic lupus erythematosus. Hypertension (2001) 1.68

Cloning of the cellular receptor for feline leukemia virus subgroup C (FeLV-C), a retrovirus that induces red cell aplasia. Blood (2000) 1.64

Human immunodeficiency virus type 1-infected cells in breast milk: association with immunosuppression and vitamin A deficiency. J Infect Dis (1995) 1.62

Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties. J Virol (1999) 1.61

Natural history of ischemic heart disease in relation to arteriographic findings: a twelve year study of 224 patients. Circulation (1974) 1.59

Rationale of the diet-heart statement of the American Heart Association. Report of the Nutrition Committee. Circulation (1993) 1.58

Mechanisms of clearance of Treponema pallidum from the CSF in a nonhuman primate model. Neurology (1998) 1.56

Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology (2000) 1.50

Identification of a cellular cofactor required for infection by feline leukemia virus. Science (2000) 1.49

Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol (1995) 1.47

Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology (2005) 1.43

Mechanism of death and prevalence of myocardial ischemic symptoms in the terminal event after acute myocardial infarction. Am J Cardiol (1988) 1.42

An epidemiological study of sudden and unexpected deaths in adults. Medicine (Baltimore) (1967) 1.41

Three distinct envelope domains, variably present in subgroup B feline leukemia virus recombinants, mediate Pit1 and Pit2 receptor recognition. J Virol (1997) 1.41

Normative data on the Boston Naming Test and two equivalent 30-item short forms. Clin Neuropsychol (2000) 1.40

Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. J Virol (1999) 1.37

Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol (1996) 1.35

Epidemiology of the post-polio syndrome. Am J Epidemiol (1992) 1.35

Higher blood pressure in middle-aged American adults with less education-role of multiple dietary factors: the INTERMAP study. J Hum Hypertens (2003) 1.34

Activated memory CD4(+) T helper cells repopulate the intestine early following antiretroviral therapy of simian immunodeficiency virus-infected rhesus macaques but exhibit a decreased potential to produce interleukin-2. J Virol (1999) 1.34

Experimental infection of pig-tailed macaques (Macaca nemestrina) with Campylobacter cinaedi and Campylobacter fennelliae. Infect Immun (1990) 1.34

Morphometric analysis of gray matter volume in demented older adults: exploratory analysis of the cardiovascular health study brain MRI database. Neuroepidemiology (2005) 1.32

T-cell proliferation to subinfectious SIV correlates with lack of infection after challenge of macaques. AIDS (1994) 1.32

Epidemiology of sudden death. Arch Intern Med (1972) 1.32

Progression to AIDS in macaques is associated with changes in the replication, tropism, and cytopathic properties of the simian immunodeficiency virus variant population. Virology (1995) 1.31

Transduction of Notch2 in feline leukemia virus-induced thymic lymphoma. J Virol (1996) 1.30

Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol (1998) 1.30

Phylogenetic evaluation of Kenyan HIV type 1 isolates. AIDS Res Hum Retroviruses (1997) 1.29

Cognitive test performance and presence of subclinical cardiovascular disease in the cardiovascular health study. Neuroepidemiology (2000) 1.29

An investigation of genital ulcers in Jackson, Mississippi, with use of a multiplex polymerase chain reaction assay: high prevalence of chancroid and human immunodeficiency virus infection. J Infect Dis (1998) 1.26

Mucosal transmission of pathogenic CXCR4-utilizing SHIVSF33A variants in rhesus macaques. Virology (1998) 1.24

In vivo evolution of a novel, syncytium-inducing and cytopathic feline leukemia virus variant. J Virol (1998) 1.23

Breast cancer treated at the Johns Hopkins Hospital, 1951-1956. Review of international ten-year survival rates. Cancer (1966) 1.22

Protection of macaques against simian AIDS by immunization with a recombinant vaccinia virus expressing the envelope glycoproteins of simian type D retrovirus. Proc Natl Acad Sci U S A (1989) 1.21

Sudden and unexpected non-traumatic deaths in adults: a review of epidemiological and clinical studies. J Chronic Dis (1967) 1.20

Quality of death certificate diagnoses of arterioscleroti heart disease. Public Health Rep (1967) 1.19

Identification of envelope determinants of feline leukemia virus subgroup B that permit infection and gene transfer to cells expressing human Pit1 or Pit2. J Virol (2001) 1.18

Molecular ecological analysis of porcine ileal microbiota responses to antimicrobial growth promoters. J Anim Sci (2003) 1.16

Evolution of feline leukemia virus variant genomes with insertions, deletions, and defective envelope genes in infected cats with tumors. J Virol (1994) 1.16

Replication and persistence of simian immunodeficiency virus variants after passage in macaque lymphocytes and established human cell lines. J Virol (1993) 1.15

Specificity in receptor usage by T-cell-tropic feline leukemia viruses: implications for the in vivo tropism of immunodeficiency-inducing variants. J Virol (2001) 1.15

Optimal resources for primary prevention of atherosclerotic diseases. Atherosclerosis Study Group. Circulation (1984) 1.14

Occupational noise exposure, noise-induced hearing loss, and the epidemiology of high blood pressure. Am J Epidemiol (1985) 1.13

Criteria for evaluation of automated blood pressure measuring devices for use in hypertensive screening programs. A report of the Committee on Criteria and Methods of the Council on Epidemiology, American Heart Association. Circulation (1974) 1.11

Cigarette smoking and strokes. Stroke (1974) 1.11

Cervical and vaginal shedding of human immunodeficiency virus type 1-infected cells throughout the menstrual cycle. J Infect Dis (1998) 1.11

Evidence that an IRES within the Notch2 coding region can direct expression of a nuclear form of the protein. Mol Cell (2000) 1.10

The cytopathicity of a simian immunodeficiency virus Mne variant is determined by mutations in Gag and Env. J Virol (1997) 1.07

OSMOTIC QUANTITIES IN GROWING COTTON BOLLS. Plant Physiol (1944) 1.07

Prevalence and clinical implications of American Diabetes Association-defined diabetes and other categories of glucose dysregulation in older adults: the health, aging and body composition study. J Clin Epidemiol (2001) 1.07

A prospective study of risk factors for herpes simplex virus type 2 acquisition among high-risk HIV-1 seronegative women in Kenya. Sex Transm Infect (2009) 1.06

Effect of intrauterine device use on cervical shedding of HIV-1 DNA. AIDS (1999) 1.03

Feline leukemia virus envelope sequences that affect T-cell tropism and syncytium formation are not part of known receptor-binding domains. J Virol (2000) 1.03

Was there an epidemic of diabetes in nonwhite adolescents in Allegheny County, Pennsylvania? Diabetes Care (1998) 1.02

Virus entry via the alternative coreceptors CCR3 and FPRL1 differs by human immunodeficiency virus type 1 subtype. J Virol (2009) 1.02

Cervical shedding of cytomegalovirus in human immunodeficiency virus type 1-infected women. J Med Virol (1999) 1.02

Protection from pathogenic SIV challenge using multigenic DNA vaccines. Immunol Lett (1999) 1.01

Selenium deficiency is associated with shedding of HIV-1--infected cells in the female genital tract. J Acquir Immune Defic Syndr (2001) 1.01

Isolation of a novel subgroup B feline leukemia virus from a cat infected with FeLV-A. Virology (1994) 1.01